Comparative efficacy and safety of Sofosbuvir/Velpatasvir and Danoprevir for the treatment of chronic hepatitis C: the real-world data in China

Comparative efficacy and safety of Sofosbuvir/Velpatasvir and Danoprevir for the treatment of chronic hepatitis C: the real-world data in China

Abstract Background Sofosbuvir/Velpatasvir (Epclusa, ECS) is the first pan-genotype direct-acting antiviral agent (DAA) for hepatitis C virus (HCV) infection, and Danoprevir (DNV) is the first DAA developed by a Chinese local enterprise, which is suitable for combined use with other drugs to treat g...

Full description

Bibliographic Details
Main Authors: Yunjing Zhou, Minfeng Liang, Yiting Li, Xing Chen, Jie Yang, Honglian Bai, Yingzi Long, Xiaohong Zhang, Chaoshuang Lin
Format: Article
Language:English
Published: BMC 2024-02-01
Series:BMC Gastroenterology
Subjects:
Sofosbuvir/Velpatasvir
Danoprevir
HCV genotype
Virological response
Adverse effects
Online Access:https://doi.org/10.1186/s12876-024-03147-5

Internet

https://doi.org/10.1186/s12876-024-03147-5

Similar Items